VANCOUVER, BRITISH COLUMBIA, Oct 28, 2004 (CCNMatthews via COMTEX) -- Meridian Co., Ltd. ("Meridian") (MRDAF), is pleased to announce that its subsidiary, Meridian Medical Inc. ("MMI" or "the Company") has commenced discussions regarding a collaborative study with Thorne Research Inc. ("Thorne"). The study will use the Digital Pulse Analyzer ("DPA") to test the effectiveness of Thorne's new product - Perfusia-SR. Perfusia-SR is a supplement that represents a revolutionary advancement in nutritional support for the heart and blood vessels. Perfusia-SR is a proprietary sustained-release L-arginine, which provides the body a constant source of nitric oxide, a substance vital in many metabolic processes in the body, especially the lining of the arteries.
The DPA has the capability to measure the efficacy of treatment programs, including neutraceutical supplementation, by measuring the response of small and large artery compliance, which provides critical information regarding arterial health and aging.
MMI met representatives of Thorne Research at the American Association of Naturopathic Physicians Convention in September 2004. The two companies quickly realized the collaborative potential, combining MMI's technology and substantial attendance at its exhibit booths, and Thorne Research's superior cardiovascular product.
MMI is also in negotiations with other neutraceutical companies for upcoming conferences and collaborations. The Company is finding a large target market for its technology with companies that sell products for cardiovascular health and related health issues such as diabetes and obesity.
More About: Digital Pulse Analyzer ("DPA")
The "DPA" accurately measures the elasticity of small and large arteries and provides health care practitioners with critical information regarding arterial aging. This FDA approved device is inexpensive, non-invasive, and can provide results in minutes. Accumulating evidence suggests that abnormalities in the pulsatile characteristics of arteries occur early in the disease process associated with increased cardiovascular risk, and can be favorably modified by therapeutic interventions.
The Company feels that use of the "DPA" can help caregivers reduce cardiovascular disease in their patient populations through early detection and prevention, and ultimately assist to decrease the associated financial costs placed on the health care industry. Cardiovascular disease is the #1 killer in the United States with an estimated economic cost of approximately $298 billion.
More About: Thorne
Since 1984, Thorne has earned the trust of thousands of health-care practitioners worldwide. Confidence in Thorne is the single most important reason practitioners turn to their products for their critical nutritional supplement needs.
In this competitive industry the amount of dollars spent on advertising is tremendous, with all companies claiming they have the best products. Thorne Research's reputation wasn't shaped through clever marketing, but rather, through the unbiased scrutiny and approval of health-care practitioners throughout the world who discovered one important detail - their products consistently produced positive results in their patients.
More About: Meridian
Meridian is an established leader in the research/development, manufacturing, and sales of integrative medical diagnostic equipment. The company sells its products and equipment to a wide array of customers in the global health care industry. The company presently holds a total of 18 worldwide patents on its technology, and has received FDA, as well as other international regulatory approvals for many of its products.
Meridian is committed to the ongoing global research and advancement of integrative medical products that contribute to the better health of humanity.